Loading
A phase 2 trial of fOLFIRINOX / mFOLFIRINOX and pembrolizumab in pancreatic cancer, run by Icahn School of Medicine at Mount Sinai, now recruiting.
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT05462496 by Icahn School of Medicine at Mount Sinai, with a registry enrolment figure of 25 participants, started 2023-03-16 and due to reach its primary completion in 2027-08. Interventions recorded: Biopsy; FOLFIRINOX; Ciprofloxacin; Metronidazole; Pembrolizumab; Surgical Resection. Conditions listed: Pancreatic Cancer. Primary outcome: Achievement of overall immune response; Achievement of overall immune response. Pancreatic eligibility wording from the registry: "* Histologically confirmed pancreatic adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/